Publication

Video

Supplements and Featured Publications

Milestones in Medicine: Updates in AML
Volume1
Issue 1

Dr. Kadia on E-selectin as a Target in the Treatment of AML

Tapan M. Kadia, MD, discusses the use of E-selectin as a target for treatment in acute myeloid leukemia.

Tapan M. Kadia, MD, associate professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the use of E-selectin as a target for treatment in acute myeloid leukemia (AML).

E-selectin is a marker that is present in the tumor microenvironment for patients with AML, Kadia says. E-selectin serves as a marker that binds to leukemia cells, protecting them by activating cell survival and growth pathways and promoting resistance to chemotherapy in AML, Kadia explains.

By disrupting the interaction of E-selectin and leukemia cells in the tumor microenvironment, AML cells can become more sensitive to chemotherapy, Kadia notes. Uproleselan, a novel E-selectin antagonist, is designed to bind to E-selectin to make AML cells more vulnerable to systemic treatments, potentially leading to better outcomes, response rates, and long-term survival for patients with AML, Kadia concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity